PDF(Pubmed)
Abstract：
Nanocapsules provide selective delivery and increase the bioavailability of bioactive compounds. In this study, we examined the anticancer and immunomodulatory potential of Fridericia chica (crajiru) extract encapsulated in nanocapsules targeting myeloid leukemias. Nanocapsules containing crajiru (nanocapsules-CRJ) were prepared via interfacial polymer deposition and solvent displacement. Size and polydispersity were measured by dynamic light scattering. Biological assays were performed on leukemia cell lines HL60 and K562 and on non-cancerous Vero cells and human PBMC. The anticancer activity was evaluated using cytotoxicity and clonogenic assays, while the immunomodulatory activity was evaluated by measuring the levels of pro- and anti-inflammatory cytokines in PBMC supernatants treated with concentrations of nanocapsules-CRJ. Nanocapsules-CRJ exhibited significant cytotoxic activity against HL60 and K562 cells at concentrations ranging from 0.75 to 50 μg/mL, with the greatest reductions in cell viability observed at 50 μg/mL (p < 0.001 for HL60; p < 0.01 for K562), while not affecting non-cancerous Vero cells and human PBMCs. At concentrations of 25 μg/mL and 50 μg/mL, nanocapsules-CRJ reduced the formation of HL60 and K562 colonies by more than 90% (p < 0.0001). Additionally, at a concentration of 12 μg/mL, nanocapsules-CRJ induced the production of the cytokines IL-6 (p = 0.0002), IL-10 (p = 0.0005), IL-12 (p = 0.001), and TNF-α (p = 0.005), indicating their immunomodulatory potential. These findings suggest that nanocapsules-CRJ hold promise as a potential therapeutic agent with both cytotoxic and immunomodulatory properties.
摘要：
纳米胶囊提供选择性递送并增加生物活性化合物的生物利用度。在这项研究中,我们研究了封装在靶向髓系白血病的纳米胶囊中的Fridericiachica（crajiru）提取物的抗癌和免疫调节潜力。通过界面聚合物沉积和溶剂置换制备含有crajiru（纳米胶囊-CRJ）的纳米胶囊。通过动态光散射测量尺寸和多分散性。对白血病细胞系HL60和K562以及非癌Vero细胞和人PBMC进行生物学测定。使用细胞毒性和克隆形成试验评估抗癌活性，而免疫调节活性是通过测量用一定浓度的纳米胶囊-CRJ处理的PBMC上清液中促炎和抗炎细胞因子的水平来评估的。纳米胶囊-CRJ在0.75至50μg/mL的浓度范围内对HL60和K562细胞表现出显著的细胞毒性活性，在50μg/mL时观察到细胞活力的最大降低（HL60的p<0.001；K562的p<0.01），而不影响非癌Vero细胞和人PBMC。在浓度为25μg/mL和50μg/mL时，纳米胶囊-CRJ使HL60和K562菌落的形成减少了90%以上(p<0.0001)。此外,浓度为12μg/mL，纳米胶囊-CRJ诱导细胞因子IL-6的产生（p=0.0002），IL-10（p=0.0005），IL-12（p=0.001），和TNF-α（p=0.005），表明它们的免疫调节潜力。这些发现表明纳米胶囊-CRJ有望作为具有细胞毒性和免疫调节特性的潜在治疗剂。
